Evotec's CEO Explains Logic Behind Drug Discovery Pact With Novo Nordisk

23 Aug 2018

• By Sten Stovall

Novo Nordisk's R&D pact with Evotec will open therapeutic possibilities for the Danish group in diabetes and obesity using small molecules, says Evotec's CEO.

Researchers — Novo Nordisk Is Tapping External Know-How with Its Evotec Pact • Source: Shutterstock

Evotec AG hopes its just-inked strategic pact with Novo Nordisk AS will move steadily from its preclinical stages – based on IP held by the Danish group – to a long-term drug discovery and development alliance in which the duo jointly own the assets.

That's the view expressed to Scrip by the Austrian biotech's CEO, Werner Lanthaler.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

06 Jun 2025

• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

04 Jun 2025

• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.